Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Observational 3Interventional 1

Sponsor

Cancer Type

NET 4Endocrine 4

Conditions

Papillomavirus Infections 9Uterine Cervical Neoplasms 4Neuroendocrine Tumors 4Autoimmune Diseases 3Prostatic Neoplasms 2Neoplasms 2Abortion, Spontaneous 2Recurrence 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Neuroblastoma 1Neoplastic Cells, Circulating 1Neoplasm Metastasis 1Myasthenia Gravis 1Lymphohistiocytosis, Hemophagocytic 1Lung Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Everolimus 15surufatinib 7lutetium Lu 177 dotatate 6lanreotide 6amino-acid, glucose, and electrolyte solution 5Octreotide 5Sunitinib 4Data Collection 4pasireotide 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3tislelizumab 2pembrolizumab 2fosbretabulin 2arginyllysine 2Temozolomide 2Paclitaxel 2PM 01183 2Irinotecan 2Carboplatin 264Cu-SARTATE 23-Iodobenzylguanidine 2toripalimab 1telotristat ethyl 1taxane 1repotrectinib 1pralsetinib 1pelcitoclax 1liposomal doxorubicin 1gadoteridol 1gadoterate meglumine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Neuroendocrine Tumors × Data Collection × Clear all
NCT05017662 2025-09-04

A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072

Ariceum Therapeutics GmbH

Phase NA Completed
20 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03562091 2020-08-28

OPERA

Ipsen

Completed
115 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03112694 2020-06-02

Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors

Ipsen

Completed
93 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03220087 2018-12-21

RECOSY

Ipsen

Completed
142 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡